Scn7A Protein (Sodium Voltage Gated Channel Alpha Subunit 7) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
:: infobox .infobox-protein
| SCN7A Protein (Sodium Voltage-Gated Channel Alpha Subunit 7) | |
|---|---|
| Gene | SCN7A |
| UniProt | Q9UQD0 |
| Molecular Weight | ~220 kDa |
| Subcellular Localization | Plasma membrane |
| Protein Family | Voltage-gated sodium channel family |
| Aliases | Nav1.7, NaG, Nav1.7a |
===
SCN7A encodes the Nav1.7 sodium channel alpha subunit. The protein contains four domains (I-IV), each with six transmembrane segments (S1-S6). The channel is approximately 2000 amino acids and forms a functional sodium channel when associated with auxiliary beta subunits.
Nav1.7 regulates neuronal excitability:
SCN7A variants cause:
SCN7A mutations are associated with epileptic encephalopathy.
Nav1.7 dysregulation contributes to migraine pathogenesis.
Nav1.7 is a major pain target:
The study of Scn7A Protein (Sodium Voltage Gated Channel Alpha Subunit 7) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The SCN7A Protein is a protein involved in various cellular processes in the nervous system. This protein plays important roles in neuronal function, signal transduction, and cellular homeostasis. Dysfunction of this protein has been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
The SCN7A Protein participates in multiple molecular pathways critical for neuronal health. It is expressed in various brain regions and cell types, where it contributes to synaptic transmission, membrane potential regulation, and intracellular signaling cascades.
Alterations in SCN7A Protein expression or function have been associated with several neurodegenerative conditions. Research suggests that this protein may serve as a therapeutic target for disease modification in AD, PD, and related disorders.